Study points to promising chemoimmunotherapy strategy for aggressive stage III non-small cell lung cancer

A study led by Dana-Farber Cancer Institute researchers found that combining chemotherapy and immunotherapy before surgery for patients with aggressive stage III non-small cell lung cancer that is considered difficult or impossible to surgically remove can help shrink tumors and make surgery possible.

…